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Abstract
Background: The Food and Drug Administration (FDA) approved drug labels contain a broad array of information,
ranging from adverse drug reactions (ADRs) to drug efficacy, risk-benefit consideration, and more. However, the
labeling language used to describe these information is free text often containing ambiguous semantic
descriptions, which poses a great challenge in retrieving useful information from the labeling text in a consistent
and accurate fashion for comparative analysis across drugs. Consequently, this task has largely relied on the manual
reading of the full text by experts, which is time consuming and labor intensive.
Method: In this study, a novel text mining method with unsupervised learning in nature, called topic modeling, was
applied to the drug labeling with a goal of discovering “topics” that group drugs with similar safety concerns and/or
therapeutic uses together. A total of 794 FDA-approved drug labels were used in this study. First, the three labeling
sections (i.e., Boxed Warning, Warnings and Precautions, Adverse Reactions) of each drug label were processed by
the Medical Dictionary for Regulatory Activities (MedDRA) to convert the free text of each label to the standard ADR
terms. Next, the topic modeling approach with latent Dirichlet allocation (LDA) was applied to generate 100 topics,
each associated with a set of drugs grouped together based on the probability analysis. Lastly, the efficacy of the
topic modeling was evaluated based on known information about the therapeutic uses and safety data of drugs.
Results: The results demonstrate that drugs grouped by topics are associated with the same safety concerns and/or
therapeutic uses with statistical significance (P<0.05). The identified topics have distinct context that can be directly linked
to specific adverse events (e.g., liver injury or kidney injury) or therapeutic application (e.g., antiinfectives for systemic use).
We were also able to identify potential adverse events that might arise from specific medications via topics.
Conclusions: The successful application of topic modeling on the FDA drug labeling demonstrates its potential
utility as a hypothesis generation means to infer hidden relationships of concepts such as, in this study, drug safety
and therapeutic use in the study of biomedical documents.
Background
The number of text documents available from published
literature and other public domain repositories is rapidly
expanding. Retrieving relevant information from the
ever-increasing corpora is a daunting task [1]. One active
research area is to extract/discover the relationships of
different concepts (e.g., drugs, diseases, and mechanisms)
presented in the documents using computational means.
For example, Swanson [2] applied Literature Based
Discovery (LBD) methods to identify hidden relationships
between concepts in the literature. His study demon-
strated that although there is no clear relationship
between concepts A and C in the literature, their associa-
tion can be established through concept B that links
concepts A and C separately. Swanson studied the rela-
tionship between fish-oil (concept A) and Raynaud’sd i s -
ease (concept C) through blood viscosity (concept B) and
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any medium, provided the original work is properly cited.suggested that fish-oil could be used for the treatment of
Raynaud’s disease.
Another commonly used approach is based on concur-
rence of terms (e.g., words) in documents, referred to as a
“bag of words” or “term frequency and inverse document
frequency” (tf-idf) approach [3]. Gordon and Lindsay [4]
replicated the Swanson’s discovery using this approach by
mining the Medline database and were able to confirm the
fish-oil and Raynaud’s disease relationship. However, such
methods like tf-idf fail to identify syntactic and semantic
relationships between words in the documents. For exam-
ple, a search for the word “drug” may not return a docu-
ment containing the word “medicine”, although both are
used for the same context in most cases. Consequently,
latent semantic indexing (LSI) was introduced [5], which
represents terms and documents as vectors in a concept
space by using singular value decomposition (SVD) [3].
Gordon and Dumais [6] employed LSI to uncover the rela-
tionship between fish-oil and Raynaud’s disease using the
Medline database as a classic case to assess their metho-
dology. The major limitation of LSI is that the derived
concepts represented by singular vectors are difficult to
interpret.
Recently, topic modeling such as probabilistic LSI
(pLSI) [7] and latent Dirichleta l l o c a t i o n( L D A )[ 8 ]h a v e
been used widely in the field of computer science with a
specific focus on text mining and information retrieval.
In topic modeling, documents are a mixture of “topics”,
where a topic consists of a set of words that frequently
(measured as a probability) occurs together across the
documents. The probabilistic nature of topic modeling
preserves the contents of the documents, represented by
words through topics. In contrast to LBD where the aim
is to discover possible association between concepts that
represented by the words, topic modeling does not focus
on the mutual relations between words. Rather, it
uncovers the relationship between topics representing
documents via words. Consequently, instead of focusing
on co-occurrence and association between words (con-
cepts), topic modeling explores the probabilistic pattern
among topics which do not require a transitive relation
of words, i.e., A®B®C. Another distinction is that topic
modeling is not dependent on the assumption of disjoint
literature or datasets while LBD is defined as the process
of finding the complementary structures from disjoint
science literature.
One major advantage of topic modeling (e.g., pLSI)
over LSI is that each topic is interpretable in the form
of a probability distribution over words. In a study by
Blei and Lafferty [9], the authors compared pLSI with
LDA (a generalization of pLSI) by mining articles pub-
lished in the journal Science from 1990-1999. The study
suggested that topic modeling can be an effective
method to extract meaning from large collections of
documents, and that LDA results in more reasonable
mixtures of topics in a document compared to pLSI. To
the best of our knowledge, topic modeling has not yet
been extensively investigated in medical and biological
sciences [10-14] where textual documents are still the
predominant resource used to archive research findings,
clinical practices, regulatory actions, etc.
For example, the legally regulated drug labels approved
by the Food and Drug Administration (FDA) [15-17] con-
tain valuable information about adverse drug reactions
(ADRs) and among other things. The information
embedded in these documents are obtained from clinical
trials and post-marketing surveillance. The FDA-approved
drug labeling text has been a rich resource for study of
drug related safety concerns and toxicity, such as drug-
induced liver injury [18,19]. For example, studies based on
the drug labeling have revealed that drugs receiving black
box warnings appear more often in certain therapeutic
categories than others [20,21].
In this study, we evaluated the utility of topic modeling
to extract safety information from FDA-approved drug
labeling text. Figure 1 shows an overview of our methodol-
ogy. Our objective is to demonstrate how topic modeling,
as an unsupervised learning technique, can contribute as a
new venue to the study of drug safety, drug use, and phar-
macovigilance. Our results demonstrated that topic mod-
eling can group and classify drugs based on their shared
commonalities (such as safety profiles and therapeutic
uses) with no need of a priori knowledge, and thus holds
the potential for broad applications in biomedical research,
particularly for the FDA documents.
Methods
Drug label data set
The FDA drug labeling text was obtained from DailyMed
(http://dailymed.nlm.nih.gov/dailymed/), where most
FDA-approved prescription drug labels were available.
We noticed that a drug was often associated with multi-
ple labels, different names could be used for the same
drug, or the administration route could vary for the same
drug. Thus, a set of inclusion/exclusion criteria were
used for the preprocessing of the drug labels to generate
a “one drug with one label” data set: 1) the labels for the
same drug were grouped together using the generic
name; 2) for each drug, the latest version of the drug
label was used according to its effective date; 3) drugs
containing more than one active ingredient were
excluded; 4) only small molecular drugs were included;
and 5) only prescription drugs with tablet or capsule
types and intravenous routes were considered.
After the preprocessing, 794 unique drugs remained.
T h i r t y - f i v ep e r c e n t( 2 7 9 )o ft h e s eh a daB o x e dW a r n i n g
(BW), the most severe label associated with ADRs. The
BW information was used to assess the performance of
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concerns. In addition, 635 drugs out of 794 drugs can be
defined by the first level of the Anatomical Therapeutic
Chemical Classification System (ATC) (http://www.who.
int/classifications/atcddd/en/). These data were used to
evaluate topic modeling’s performance in the identifica-
tion of topics related to therapeutic use.
Data processing
The extracted XML formatted labels of 794 drugs were
parsed. Three labeling sections, namely BW, Warnings
and Precautions (WP), and Adverse Reactions (AR)
were used for further analysis. These three sections con-
tain the labeling information about safety concerns,
adverse events, and cautions that should be considered
in the clinical use of the drug. We filtered the raw text
based on the standard ADR terms of the Medical Dic-
tionary for Regulatory Activities (MedDRA) (http://
www.meddramsso.com/), and created separate text
documents for every drug. Specifically, the lowest level
of terms in the MedDRA database was used with 68,259
terms from 26 organs [22]. Consequently, we built an
ADR profile for each drug with the standard terms from
MedDRA, which was the input for the following topic
modeling.
Topic modeling
Topic modeling is based on the idea that a document is a
mixture of topics, and that each word is selected with a
probability given one of the document topics. More spe-
cifically, let P(z) be the distribution of topics for a given
document, and P(w|z) be the probability distribution over
Figure 1 Overview of the workflow. The MedDRA ontology was applied to the three drug labeling sections (i.e., Boxed Warnings, Warnings
and Precautions, and Adverse Reactions) to generate a list of adverse event terms for each drug, on which topic modeling was applied,
followed with statistical analysis to assess the identified topics in the context of safety concern and therapeutic use.
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index for i-th word) of a document is generated in two
steps: first, a topic j is selected with a probability of P
(zi=j) following the probability distribution P(z); second, a
word wi is picked out with a probability of P(wi | zi=j).
Then the two-step generative process specifies the fol-
lowing distribution of words in a document:
Pw Pw z jPz j ii i i
j
T
() (| ) ( ) == =
= ∑
1
where T represents the number of topics.
For document d, θ
(d) = P(z) stands for the multinomial
distribution over topics. In the pLSI model, there are no
assumptions on how the θ’s are generated [7]. The LDA
m o d e lb yB l e ia n dL a f f e r t y[ 9 ]i sag e n e r a t i v em o d e l ,
where a Dirichlet prior on θ makes not only the infer-
ence step more convenient, but also the model more
generative for new documents [8].
In this study, we used the LDA approach to obtain the
parameter θ for every document (i.e., the drug labels). The
topics were extracted by using Mallet, an open source soft-
ware package from UMASS [23]. We used 100 as the
number of topics to carry out the analysis and calculated
the conditional probability of each topic given a drug, as
illustrated in Figure 1 (the left table in the middle panel).
Since it is a probability distribution over topics, the row-
wise summation is equal to 1.
Drug grouping
The topic distribution measures the connection (or relat-
edness) of a drug with a specific topic (i.e., the conditional
probability of topic for a given drug as shown in the table
on the left of Figure 1). We used this statistical probability
to group the drugs by associating them with topics. More
specifically, the drugs were assigned to the most probable
topics for the given drugs. The result of this topic assign-
ment is illustrated in the table on the right of Figure 1,
where each row has exactly one entry with the value 1,
which indicates the assigned topic for the given drug (all
other entries are 0). In the case of a tie, we arbitrarily
assigned the drug to any of the topics with maximal condi-
tional probability of topics for given drugs.
Results
Figure 1 illustrates the flowchart of this study. The 794
FDA-approved drug labels were processed and the three
labeling sections (i.e., BW [24], WP[17], and AR [15,25])
were extracted. Then, the MedDRA ontology was used to
convert the free text of each label to standard ADR terms.
Afterwards, topics were generated by using LDA followed
by assigning each drug to the most probable topic. Finally,
the efficacy of the topic modeling was evaluated based on
the ATC and BW labels of the drugs to examine the rela-
tionship of the identified topics with therapeutic use and
safety, respectively.
The analysis resulted in 100 topics that were ranked
according to the number of drugs in each topic, as
depicted in Figure 2. We analyzed the common proper-
ties shared by the drugs in each topic. In order to
achieve a meaningful statistical test and to avoid bias,
we chose topics containing at least 10 drugs for asses-
sing their relevance to therapeutic uses and safety con-
cerns by using ATC and BW labels, respectively. A total
of 27 topics (the first 27 bars in Figure 2 and Additional
file 1) were selected for the following enrichment
analysis.
Topic analysis in terms of BW
BW has been defined by the regulatory document
(21CFR201.57) as “certain contraindications or serious
warnings, particularly those that may lead to death or
serious injury.” It is the strongest medication-related
safety warning that the FDA c a ni s s u ef o rap r e s c r i p t i o n
drug, and such a decision issued by the FDA has serious
implications for the licensed practitioner, the pharmacist,
the patient, the pharmaceutical manufacturer, and the
distributor [18,19]. Thus, a topic populated with BW
drugs is likely related to drug safety.
There were 455 drugs involved in the aforementioned
27 topics (57% of the total 794 drugs in 100 topics).
Among these 455 drugs were 188 that had BW (41%).
Figure 3 shows the percentage of BW drugs in each of
the 27 topics. Five topics (5, 6, 8, 18, and 24) contained at
least 70% of the drugs with BW in each topic. Table 1
shows the statistical analysis of these five topics by using
Fisher’se x a c tt test. All five topics had a p-value of less
than 0.05. The content varied between topics; for exam-
ple, drugs grouped in topic 24 are related to liver injury,
while those classified under topic 5 could cause kidney
injury.
The results indicated that topic modeling can yield
statistically significant topics that group and identify
drugs with severe safety concerns using FDA-approved
drug labels. Next, we further assessed the performance
of the topic modeling in deriving topics that represent
therapeutic uses of drugs.
Topic analysis in terms of therapeutic use
The aforementioned analysis procedure was similarly
conducted to investigate whether topic modeling can
group and classify different drugs according to their
therapeutic use. The drugs were mapped to the first
level of ATC codes. The 455 drugs in the 27 topics cov-
ered all 14 categories of the first level of ATC. Five
topics (1, 4, 6, 18, and 22) were identified as containing
>70% drugs belonging to at least one of the 14 ATC
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0.05, Table 2). These topics were related to drugs used
for Nervous System disorders (topics 6, 18, and 22),
Antiinfectives for Systemic Use (topic 4), and Antineo-
plastic and Immunomodulating Agents (topic 1).
We listed the ADR terms for each of five topics in
Table 2 to examine which side effects might arise from
medications in these topics. We found that there exists
a distinct difference in adverse reactions for topics 6, 18
and 22 although they are all used for Nervous System
disorders. The drugs in topic 18 had a significant impact
on elderly persons with dementia and may cause death,
while the drugs in topic 6 could cause anxiety, irritation,
and even suicide attempts. Compared to topics 6 and
18, the side effects for the drugs in topic 22 were much
milder, and include sleep disturbance and depression.
Discussion
Techniques such as bag of words and latent semantic
analysis have been commonly used in text mining.
Recently, topic modeling has proven to be a robust
approach for text mining with distinct advantages over
Figure 2 The distribution of the number of drugs in the 100 topics. The cutoff for topics to perform further analysis on was set at 10 drugs
and is shown on the graph.
Figure 3 The percentage of drugs with Boxed Warning (BW) for 27 topics. This percentage was calculated for each of 27 topics that
contain at least 10 drugs.
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to apply topic modeling to FDA-approved drug labels.
Our approach consisted of two main steps. First, for
each drug, we inferred the topics from a mixture of
standard adverse reaction terms. Second, the drugs were
grouped based on the shared topics. Our results demon-
strate that topic modeling offers several distinct advan-
tages, particularly when applied to drug labels. First, as
an unsupervised learning technique, it does not require
any training data or ap r i o r iknowledge about drug
labels. Second, it can discover the gist and hidden pat-
terns in the labels. Furthermore, the discovered topics
can be successfully used for grouping and identifying
drugs within the same therapeutic category as well as
drugs with severe safety concerns. Last but not least, the
discovered topics can be easily interpreted by using
some domain specific knowledge.
According to the theory of topic modeling, each topic
represents certain common properties, which reflects the
pattern in the free texts. The topics populated with more
drugs do not necessarily correlate with the degree of
shared commonality among drugs. Finding out the exact
meanings of the topics requires additional information
and domain knowledge. In this study, we evaluated
whether the topic modeling can generate biologically
relevant topics from the drug labeling text. Since the
drug labeling text contains information largely related to
safety and therapeutic use, we tested the topic modeling
using the drugs with ATC and BW labels.
We identified five topics each that were significant in
the therapeutic application and safety concerns of drugs,
respectively. Most topics of safety concern are different
from these for therapeutic application except two; topics
6 and 18 were significant in both therapeutic use and
Table 1 Five topics with highly populated BW drugs (>70%)
Topics Statistics Corresponding ADRs from MedDRA
# drugs # BW Drugs % P-value
Topic 5 21 15 71% 0.0121 Creatinine; renal-failure; hyperkalemia; potassium; injury
Topic 6 20 16 80% 0.0014 Suicide; irritability; restlessness; agitation; anxiety
Topic 8 19 14 74% 0.01 Bleeding; stroke; gastrointestinal-bleeding; myocardial-infarction; coronary artery bypass
Topic 18 14 13 93% 2.38E-4 Death; psychosis; elderly; dementia; extrapyramidal symptoms
Topic 24 11 9 82% 0.0135 Hepatitis; hepatotoxicity; hepatic-failure; injury; death
Figure 4 The purity of the top therapeutic category for 27 topics. Each of 27 topics was assigned to one therapeutic category according to
which ATC category contained the most drugs from that topic; the percent of drugs belonging to that category from the topic is shown.
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are not only used for the same therapeutic purpose, but
the adverse reactions related to this medication are so
severe that their uses need to be regulated with BW.
This result also indicates that a topic is not necessary
associated with only one concept, and it could be related
to several commonalities shared by the drugs. However,
in order to discern the hidden meanings of a topic, care-
ful analysis and domain specific knowledge are required,
indicating that topic modeling can be a powerful
hypothesis generation tool to guide systemic investiga-
tion of the relationship between the topics and down-
stream biological actions.
We also observed that different topics might fall into
the same therapeutic category but with different biologi-
cal indication. Specifically, topics 6, 18, and 22 all belong
to the same therapeutic category, i.e., Nervous System
disorders. However, the degree of severity in adverse
reaction and the target population for application are dis-
tinctly different between drugs in different topics. The
drugs in topics 6 and 18 could associate with more ser-
ious adverse events than those in topic 22. For instance,
Mirtazapine, a drug in topic 6, is an antidepressant drug
with BW [26]. Compared to placebo, it increases the risk
of suicidal thinking and behavior (suicidality) in children,
adolescents, and young adults in short-term studies of
major depressive disorder and other psychiatric disor-
ders. This is consistent with our findings using the unsu-
pervised topic modeling method.
Understanding drug safety and efficacy continue to be
critical and challenging issues for academia, government
agencies, and pharmaceutical companies in their mutual
goal to improve patient health. FDA drug labels contain
comprehensive information for prescription drugs about
their safety and therapeutic use, which is a rich resource
to guide the development of new methodologies to under-
stand underlying mechanisms of drug toxicity and efficacy.
Given the fact that the labeling is constantly changing in
light of new data available for a drug and that the number
of labels will continually increase when new drugs are
brought into the market, we need to have an accurate and
effective methodology to mine this rich and constantly
evolving resource. Our first attempt of applying topic
modeling to the information contained in FDA drug labels
reveals its ability to group drugs together based on similar
intrinsic properties such as the patterns in therapeutic use
and safety, which could be used to study modes of action
of the grouped drugs. We believe that topic modeling also
holds potential for mining other biological documents, e.
g., the FDA’s Adverse Event Reporting System (AERS),
PubMed literature, documents from the tobacco industry,
Online Mendelian Inheritance in Man (OMIM) [27,28],
and GeneRIF [29].
Conclusions
This study investigates the efficacy of topic modeling for
the discovery of hidden patterns and their meanings
from FDA-approved drug labels. The results demon-
strate that drug groups based on topics are statistically
significantly enriched in terms of either drug safety cate-
gories or therapeutic categories. Topic modeling could
thus offer a novel way to discern inter-relationships
among drug, target, ADR, gene, pathway, and disease
data from public biomedical literature and drug data-
bases. We conclude that topic modeling is a promising
unsupervised learning technique for mining biomedical
documents by retrieving, organizing, and integrating
information from a textual database for drug safety,
pharmacovigilance, and drug repositioning.
Disclaimer
The views presented in this article do not necessarily
reflect those of the US Food and Drug Administration.
Additional material
Additional file 1: Drug list for 27 topics.
Table 2 Five topics with highly populated drugs (>70%) in a therapeutic category
Topics Statistics Corresponding ADRs from MedDRA
#
drugs
Therapeutic categories (First Level of ATC) % P-value
Topic
1
31 Antineoplastic and immunomodulating
agents (L/24)
81% 0.0005 Neutropenia; stomatitis; infection; myelosuppression; sepsis;
immunosuppression
Topic
4
21 Antiinfectives for systemic use (J/19) 96% 0.0005 Colitis; diarrhea; allergy; colectomy; eosinophilia
Topic
6
20 Nervous system (N/14) 73% 0.0011 Suicide; irritability; restlessness; agitation; anxiety
Topic
18
14 Nervous system (N/11) 88% 8.31E-
004
Death; psychosis; elderly; dementia; extrapyramidal symptoms
Topic
22
12 Nervous system (N/8) 75% 0.020 Depression; excitement; dysphoria; unconsciousness; sleep
disturbances
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